Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART

Completed · Not applicable · Has a placebo group

Conditions studied: Hyperlipidemia, HIV Infections

In brief

Included in this study will be patients with HIV and being treated with highly active antiretroviral medications (HAART) including protease inhibitors (PI) or non-nucleoside reverse transcriptase inhibitors (NNRTI). Protease inhibitors and non-nucleoside reverse transcriptase inhibitors are very common medications in HIV treatment and are usually given with other medications as part of a standard treatment for HIV (HAART). We hope to learn more about how the levels of cholesterol-and triglyceride-carrying particles (lipoproteins) are affected by a nutritional supplement, L-Carnitine, in HIV-positive patients treated with antiretroviral medications.

Key facts

Study ID: NCT00386971
Run by: University of California, Davis
People needed: 13
Starts: 2006-10-01
Expected to finish: 2009-12-01
Last updated by the study team: 2017-05-30

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Men and Women Ages 18-70,
Stable HAART regimen x 6 mo,
PI or NNRTI based regimens,
Caucasian, African American or Hispanic patients

You may not qualify if…

Diabetes Mellitus,
Liver Disease,uncontrolled
Pregnant or nursing mothers,
BMI> 35,
Hemoglobin <11 g/dl,
Conditions known to lower seizure threshold (ie. brain tumor) or taking medications that lower seizure threshold,
Patients taking: Warfarin, ValproicAcid or Zidovudine,Wellbutrin or Effexor
Chronic Kidney Disease Stage 3-5,
Untreated Thyroid Disease,
Hormone replacement therapy,
Triglycerides >500 mg/dl (fasting)

Where it is running

GCRC UC Davis — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.